Acuna-Hidalgo Rocio, Sengul Hilal, Steehouwer Marloes, van de Vorst Maartje, Vermeulen Sita H, Kiemeney Lambertus A L M, Veltman Joris A, Gilissen Christian, Hoischen Alexander
Department of Human Genetics, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Geert Grooteplein 10, 6525 GA Nijmegen, the Netherlands.
Department of Human Genetics, Donders Institute of Neuroscience, Radboud University Medical Center, Geert Grooteplein 10, 6525 GA Nijmegen, the Netherlands.
Am J Hum Genet. 2017 Jul 6;101(1):50-64. doi: 10.1016/j.ajhg.2017.05.013. Epub 2017 Jun 29.
Clonal hematopoiesis results from somatic mutations in hematopoietic stem cells, which give an advantage to mutant cells, driving their clonal expansion and potentially leading to leukemia. The acquisition of clonal hematopoiesis-driver mutations (CHDMs) occurs with normal aging and these mutations have been detected in more than 10% of individuals ≥65 years. We aimed to examine the prevalence and characteristics of CHDMs throughout adult life. We developed a targeted re-sequencing assay combining high-throughput with ultra-high sensitivity based on single-molecule molecular inversion probes (smMIPs). Using smMIPs, we screened more than 100 loci for CHDMs in more than 2,000 blood DNA samples from population controls between 20 and 69 years of age. Loci screened included 40 regions known to drive clonal hematopoiesis when mutated and 64 novel candidate loci. We identified 224 somatic mutations throughout our cohort, of which 216 were coding mutations in known driver genes (DNMT3A, JAK2, GNAS, TET2, and ASXL1), including 196 point mutations and 20 indels. Our assay's improved sensitivity allowed us to detect mutations with variant allele frequencies as low as 0.001. CHDMs were identified in more than 20% of individuals 60 to 69 years of age and in 3% of individuals 20 to 29 years of age, approximately double the previously reported prevalence despite screening a limited set of loci. Our findings support the occurrence of clonal hematopoiesis-associated mutations as a widespread mechanism linked with aging, suggesting that mosaicism as a result of clonal evolution of cells harboring somatic mutations is a universal mechanism occurring at all ages in healthy humans.
克隆性造血源于造血干细胞中的体细胞突变,这些突变赋予突变细胞优势,促使其克隆性扩增,并有可能导致白血病。克隆性造血驱动突变(CHDMs)的获得与正常衰老过程相关,在65岁及以上的个体中,超过10%的人检测到了这些突变。我们旨在研究成年期CHDMs的患病率和特征。我们基于单分子分子倒置探针(smMIPs)开发了一种将高通量与超高灵敏度相结合的靶向重测序检测方法。使用smMIPs,我们在来自20至69岁人群对照的2000多个血液DNA样本中筛选了100多个CHDMs位点。筛选的位点包括40个已知突变时会驱动克隆性造血的区域和64个新的候选位点。我们在整个队列中鉴定出224个体细胞突变,其中216个是已知驱动基因(DNMT3A、JAK2、GNAS、TET2和ASXL1)中的编码突变,包括196个点突变和20个插入缺失突变。我们检测方法提高的灵敏度使我们能够检测到变异等位基因频率低至0.001的突变。在60至69岁的个体中,超过20%的人检测到CHDMs,在20至29岁的个体中,3%的人检测到CHDMs,尽管只筛选了有限的一组位点,但患病率约为先前报道的两倍。我们的研究结果支持克隆性造血相关突变的发生是一种与衰老相关的广泛机制,这表明携带体细胞突变的细胞克隆进化导致的嵌合体是健康人类在所有年龄段都存在的普遍机制。